Abbisko Therapeutics will present FGFR4 inhibitor Irpagratinib (ABSK011) pre-clinical data with an oral presentation at the 2024 AACR Annual Meeting. In addition, its self-development innovation CSF-1R inhibitor Pimicotinib (ABSK021) and small molecule PD-L1inhibitor update data will also be published at AACR with poster board.

Abbisko will present the following details at the 2024 AACR:

Title: Selective FGFR4 inhibitor Irpagratinib (ABSK011) exhibits broad synergistic and combinatory anti-tumor effects with other therapeutic agents in preclinical HCC models

Oral Presentation Number: 1228

Session Date and Time: 7 April, 2024, 3:05 PM - 3:20 PM

Title: CSF-1R inhibition with Pimicotinib (ABSK021) enhanced anti-tumor efficacy of KRASG12C inhibitors in preclinical non-small cell lung cancer mouse models

Poster Number: LB077

Poster Section：54

Session Date and Time：7 April, 2024, 1:30 PM - 5:00 PM

Title: Cellular characterization of small molecule PD-L1 inhibitors reveal their novel mechanisms of action

Poster Number：2039

Poster Section：27

Session Date and Time:  8 April, 2024, 9:00 AM - 12:30 PM